Elvucitabine

艾夫他滨

Report date: 2025/06/26 20:00:07
NME

Base Information

Drug NameElvucitabine
Drug Alias NameelvucitabinaelvucitabinumelvucitabineBeta-LFD4CL-D4FC +[9] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitorsHBV DNA Polymerase inhibitors
TargetsReverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsHepatitis B, ChronicHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaYugoslavia +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesYale University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesAlexion Pharmaceuticals IncThomas Jefferson University
Active IndicationsN/A
Inactive IndicationsHepatitis B, ChronicHIV Infections

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG